相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome
Vera A. Bittner et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Cardiovascular disease risk associated with elevated lipoprotein(a) attenuates at low low-density lipoprotein cholesterol levels in a primary prevention setting
Rutger Verbeek et al.
EUROPEAN HEART JOURNAL (2018)
Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome Analysis of the dal-Outcomes Randomized Clinical Trial
Gregory G. Schwartz et al.
JAMA CARDIOLOGY (2018)
Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies A Mendelian Randomization Analysis
Stephen Burgess et al.
JAMA CARDIOLOGY (2018)
Lipoprotein(a) and secondary prevention of atherothrombotic events: A critical appraisal
Michael B. Boffa et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2018)
Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials
Peter Willeit et al.
LANCET (2018)
Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium
Christoph Waldeyer et al.
EUROPEAN HEART JOURNAL (2017)
A Test in Context: Lipoprotein(a) Diagnosis, Prognosis, Controversies, and Emerging Therapies
Sotirios Tsimikas
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Lipoprotein(a) Improves Cardiovascular Risk Prediction Based on Established Risk Algorithms
G. Kees Hovingh et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study
Stephen Zewinger et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Apolipoprotein(a) isoform size, lipoprotein(a) concentration, and coronary artery disease: a mendelian randomisation analysis
Danish Saleheen et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials
Nicholas J. Viney et al.
LANCET (2016)
Race Is a Key Variable in Assigning Lipoprotein(a) Cutoff Values for Coronary Heart Disease Risk Assessment The Multi-Ethnic Study of Atherosclerosis
Weihua Guan et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2015)
Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin)
Amit V. Khera et al.
CIRCULATION (2014)
Discrimination and Net Reclassification of Cardiovascular Risk With Lipoprotein(a) Prospective 15-Year Outcomes in the Bruneck Study
Peter Willeit et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Lipoprotein(a) for Risk Assessment in Patients With Established Coronary Artery Disease
Michelle L. O'Donoghue et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Prediction of Cardiovascular Events in Statin-Treated Stable Coronary Patients of the Treating to New Targets Randomized Controlled Trial by Lipid and Non-Lipid Biomarkers
Benoit J. Arsenault et al.
PLOS ONE (2014)
Plasma Lipoprotein(a) Concentration Predicts Future Coronary and Cardiovascular Events in Patients With Stable Coronary Heart Disease
Paul J. Nestel et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2013)
Association between baseline lipoprotein (a) levels and restenosis after coronary stenting: Meta-analysis of 9 cohort studies
Shan-yu Qin et al.
ATHEROSCLEROSIS (2013)
When should we measure lipoprotein (a)?
Karam M. Kostner et al.
EUROPEAN HEART JOURNAL (2013)
Trends in the outcomes of percutaneous coronary intervention with the routine incorporation of fractional flow reserve in real practice
Seung-Jung Park et al.
EUROPEAN HEART JOURNAL (2013)
Extreme Lipoprotein(a) Levels and Improved Cardiovascular Risk Prediction
Pia R. Kamstrup et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Relationship of Apolipoproteins A-1 and B, and Lipoprotein(a) to Cardiovascular Outcomes The AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglyceride and Impact on Global Health Outcomes)
John J. Albers et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Optical Coherence Tomographic Analysis of In-Stent Neoatherosclerosis After Drug-Eluting Stent Implantation
Soo-Jin Kang et al.
CIRCULATION (2011)
Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study
Kåre Berg et al.
CLINICAL GENETICS (2010)
Lipoprotein(a) as a cardiovascular risk factor: current status
Borge G. Nordestgaard et al.
EUROPEAN HEART JOURNAL (2010)
Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease.
Christopher P. Cannon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction
Pia R. Kamstrup et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease
Robert Clarke et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause
MG Shlipak et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2000)
分享论文
